Cipher Pharmaceuticals Inc. (DND.TO)
-Toronto 3.71 
0.05(1.37%) May 17, 3:59PM EDT
| Prev Close: | 3.66 |
|---|
| Open: | 3.67 |
|---|
| Bid: | 3.70 |
|---|
| Ask: | 3.77 |
|---|
| 1y Target Est: | 6.25 |
|---|
| Beta: | 1.22 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.66 - 3.80 |
|---|
| 52wk Range: | 1.25 - 4.11 |
|---|
| Volume: | 9,900 |
|---|
| Avg Vol (3m): | 15,106 |
|---|
| Market Cap: | 92.81M |
|---|
| P/E (ttm): | 24.73 |
|---|
| EPS (ttm): | 0.15 |
|---|
| Div & Yield: | 2.28 (3.40%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Raising Forecasts For Cipher, Yet AgainZacks Small Cap Research(Mon, May 6)
- Q1 2013 CIPHER PHARMACEUTICALS INC Earnings Release - Before Market OpenCCBN(Fri, May 3)
- Cipher reports record financial results for Q1 2013CNW Group(Fri, May 3)
- Cipher Pharmaceuticals completes Latin American distribution and supply agreement for extended-release tramadolCNW Group(Mon, Apr 29)
- Notice of Cipher Pharmaceuticals Inc. Q1 2013 Conference Call and 2012 Annual and Special Meeting of ShareholdersCNW Group(Mon, Apr 15)
- Cipher Posts Solid 2012 Financial ResultsZacks Small Cap Research(Mon, Mar 4)
- Q4 2012 CIPHER PHARMACEUTICALS INC Earnings Release - Before Market OpenCCBN(Fri, Mar 1)
- Cipher reports record financial results for 2012CNW Group(Fri, Mar 1)
- Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2012 Conference CallCNW Group(Thu, Feb 21)
- DND.TO - Cipher Keeps Chugging AlongZacks Small Cap Research(Wed, Oct 24)
- DND.TO - Cipher's Astute DealZacks Small Cap Research(Mon, Aug 13)
- DND.TO - Cipher Posts Solid Second Quarter ResultsZacks Small Cap Research(Wed, Jul 25)
- DND.TO - Cipher Receives FDA Approval of AbsoricaZacks Small Cap Research(Tue, May 29)
Key Statistics
| Forward P/E (1 yr): | 7.42 |
|---|
| P/S (ttm): | 9.21 |
|---|
| Ex-Dividend Date: | 22-Dec-10 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.30 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.03 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company that commercializes novel formulations of marketed molecules. The company focuses on in-licensing clearly differentiated products, advancing them through the clinical devel...
View More